FACT OR FICTION? TREATMENT AND SIDE EFFECTS



Program Resource Guide

COMMON MISCONCEPTIONS IN CLL: FACT OR FICTION?

- Watch and wait can go on for years, and some CLL patients may never need treatment. FACT. Some patients may not need to be treated for their CLL.
- Patients have to take inhibitor therapies forever. FACT. Inhibitor therapies do indeed need to be taken indefinitely.
- Natural supplements help with side effects. FICTION. There is no currently no evidence that supplements can help relieve side effects.

Watch the Fact or Fiction? Treatment and Side Effects program here.

CURRENTLY APPROVED TARGETED CLL INHIBITORS

Inhibitors are targeted therapies that work by inhibiting the pathway of the genetic mutation that they target. Approved inhibitor therapies include:

BTK Inhibitor

- BCL-2 Inhibitor
- Inbrutinib (Imbruvica)

Venetoclax (Venclexta)

- PI3K Inhibitors
 - Idelalisib (Zydelig)
 - Duvelisib (Copiktra)

GLOSSARY OF TERMS

TP53 Mutation: This mutation may impact disease progression, treatment resistance and outcome for patients with CLL.

13q Deletion: Associated with a favorable outcome if other abnormalities are not present.

17p Deletion: A chromosomal abnormality found in CLL that can impact prognosis and response to treatment. Patients with a 17p deletion lack a portion of the chromosome that suppresses cancer growth.

Financial Toxicity: Issues that a cancer patient faces related to the cost of medical care, which can affect their quality of life and access to medical care.

Fluorescent in situ hybridization (FISH): A chromosome test used to identify specific genes or chromosome changes.

IGHV Mutation: CLL patients with mutated IGHV may have a longer time to treatment and can have different responses and duration of responses specific to chemotherapy.

Targeted Therapy: Treatment that blocks the growth of cancer by interfering with specific molecules involved in the progression and spread of cancer.

Watchful Waiting (or Active Surveillance): The period of time before treatment begins in which a patient is monitored for disease progression and symptoms.